Psoriasis and psoriatic arthritis have been linked to an increased prevalence of metabolic syndrome when compared to the general population. This session will review the evidence for the association between psoriatic disease and metabolic syndrome, biologic explanations for the epidemiologic association, and the relevance for clinical practice. The prevalence of metabolic syndrome in the Western European and United States ranges from 15-35% but has been found to be significantly elevated in patients with psoriasis compared to the general population in several studies. Metabolic syndrome is a combination of disorders that includes obesity, elevated fasting glucose, hypertension, and/or dyslipidemia (low high density lipoprotein and/or high triglycerides). This combination of disorders confers a significantly increased risk of major adverse cardiovascular events (MACE). It is possible that metabolic syndrome partially explains the increased risk of MACE reported in patients with psoriatic disease. The biologic basis for the link between psoriasis and metabolic syndrome is not entirely clear. Both psoriasis and obesity share increased levels of inflammatory cytokines which may promote insulin resistance, dyslipidemia and atherosclerosis. Shared genetic susceptibility loci have been identified but their impact is unclear. The individual disorders of metabolic syndrome should be identified and aggressively managed in patients with psoriatic disease.
Disclosure of Interest None Declared